PROJECT SUIVIMARY (See instructions): The Clinical Core of the Program Project Grant will perform the cognitive and clinical assessments for all subjects taking part in the Program Project Grant (PPG). The Clinical Core will recruit and assess subjects with Mild Cognitive Impairment (MCI) and will continue to follow existing Normal Healthy Control Subjects. The Core will review the study protocols with potential subjects and obtain full informed consent, perform cognitive, clinical and neurological assessments necessary for the protocol. Follow-up appointments and ongoing telephone contact with subjects will be coordinated through the Core. The Clinical Core will coordinate with the ADRC and the Aging Study to ensure accurate and timely transfer of clinical information, cognitive scores and other data relevant to the PPG dataset and subsequently to the Imaging, Methodology and Statistics (IMS) Core for data analysis and correlation with PIB PET and imaging data. The PPG Coordinating Committee comprising the Pis of the Clinical Core, Administrative Core, IMS Core, and Pis and Co-Is of the 3 projects and the PPG Administrator will oversee the Clinical Core. All of the Investigators in the Core and all of the individuals with whom they interact to achieve the aims of this Core have worked together for many years, adding to the assurance that the proposed work will be carried out appropriately.
Accurately diagnosed subjects, evaluated and followed longitudinally by skilled clinicians, is the most efficient and practical method of advancing cutting-edge PIB PET research. An experienced staff skilled in eliciting the cooperation of patients and families for PPG projects is a critical element of a well functioning PPG.
|Mizukami, Katsuyoshi; Akatsu, Hiroyasu; Abrahamson, Eric E et al. (2016) Immunohistochemical analysis of hippocampal butyrylcholinesterase: Implications for regional vulnerability in Alzheimer's disease. Neuropathology 36:135-45|
|Ikonomovic, Milos D; Abrahamson, Eric E; Price, Julie C et al. (2016) [F-18]AV-1451 positron emission tomography retention in choroid plexus: More than "off-target" binding. Ann Neurol 80:307-8|
|Perez, Sylvia E; He, Bin; Nadeem, Muhammad et al. (2015) Resilience of precuneus neurotrophic signaling pathways despite amyloid pathology in prodromal Alzheimer's disease. Biol Psychiatry 77:693-703|
|Klunk, William E; Koeppe, Robert A; Price, Julie C et al. (2015) The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement 11:1-15.e1-4|
|MarquiÃ©, Marta; Normandin, Marc D; Vanderburg, Charles R et al. (2015) Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol 78:787-800|
|Nichols, Noah; Bras, Jose M; Hernandez, Dena G et al. (2015) EIF4G1 mutations do not cause Parkinson's disease. Neurobiol Aging 36:2444.e1-4|
|Goodheart, A E; Tamburo, E; Minhas, D et al. (2015) Reduced binding of Pittsburgh Compound-B in areas of white matter hyperintensities. Neuroimage Clin 9:479-83|
|Yau, Wai-Ying Wendy; Tudorascu, Dana L; McDade, Eric M et al. (2015) Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study. Lancet Neurol 14:804-13|
|Chen, Yin J; Rosario, Bedda L; Mowrey, Wenzhu et al. (2015) Relative 11C-PiB Delivery as a Proxy of Relative CBF: Quantitative Evaluation Using Single-Session 15O-Water and 11C-PiB PET. J Nucl Med 56:1199-205|
|Mountz, James M; Laymon, Charles M; Cohen, Ann D et al. (2015) Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects. Neuroimage Clin 9:592-8|
Showing the most recent 10 out of 88 publications